Aytu BioScience gains on licensing deal to distribute sleep aid outside the US and Canada
The deal calls for SUDA Pharmaceuticals of Perth, Australia, to lead commercial development and sublicensing efforts for ZolpiMist in Europe, Asia and Latin America
Aytu BioScience Inc (NASDAQ:AYTU) strengthened Wednesday after announcing a licensing agreement to distribute its ZolpiMist oral spray sleep aid outside the US and Canada.
The arrangement calls for SUDA Pharmaceuticals Ltd of Perth, Australia, to lead commercial development and sublicensing efforts for ZolpiMist in Europe, Asia and Latin America. Aytu, based in Englewood, Colorado, has assumed a perpetual, exclusive global licensing agreement with SUDA from Magna Pharmaceuticals, the former new drug application (NDA) holder of ZolpiMist.
Shares of the company surged 32% to $1.45 in Wednesday’s Nasdaq trading.
SUD Price at posting:
0.5¢ Sentiment: Sell Disclosure: Held